Update from ASCO GI
Update from ASCO GI
How will data from ASCO GI impact the clinical management of upper and lower GI cancers?
In these podcasts, GI oncology experts share their selected highlights from ASCO GI and give their thoughts on the implications for clinical practice
How will data from ASCO GI impact the clinical management of upper and lower GI cancers?
In these podcasts, GI oncology experts share their selected highlights from ASCO GI and give their thoughts on the implications for clinical practice
Asst. Prof. Efrat Dotan, Dr. Nataliya Uboha, Prof. Shubham Pant, Prof. Andrea Sartore-Bianchi
Podcast 1: Upper GI
Dr Efrat Dotan and Dr Nataliya Uboha focus on their selected key abstracts in upper GI cancer, sharing their thoughts on how the data could influence the treatment and management of gastric/gastro-esophageal (G/GE) cancer.
Clinical takeaways:
- SPOTLIGHT trial results demonstrate the benefit of treatment with zolbetuximab + mFOLFOX in patients expressing Claudin 18.2
- In RATIONALE 305, tislelizumab, like nivolumab, shows promising results for PD-L1+ve patients
- CheckMate 649 follow up data at 3 years further supports the use of nivolumab + chemotherapy in first-line setting in patients with advanced G/GE cancer
- INTEGRATE IIa study had statistically significant results for regorafenib vs placebo in refractory advanced GE cancer. Results of INTEGRATE IIb are eagerly awaited
- The data from NEO-AEGIS make clinical decision-making between peri-operative chemotherapy and CROSS easier
- The results from INFINITY show the potential of tremelimumab + durvalumab as standard of care for patients with resectable MSI-H G/GE cancer
Podcast 2: Lower GI
Prof. Shubham Pant and Prof. Andrea Sartore-Bianchi discuss lower GI cancer and the key abstracts that they identified as potentially impacting the way we manage treatment for colorectal cancer (CRC).
Clinical takeaways:
- In SUNLIGHT, trifluridine/tipiracil plus bevacizumab improved overall survival and progression-free survival in refractory CRC patients and should be considered a standard of care in the refractory treatment setting
- In the kinetics of postoperative cfDNA/ctDNA2 study, post operative ctDNA-positivity was significantly associated with shorter recurrence-free survival. Clinical data are insufficient at this stage to consider molecular residual disease testing as standard of care for patients with resectable CRC
- Durable objective responses were observed in heavily pre-treated MSS CRC patients treated with balstilimab plus botensilimab. Further investigation is warranted
- In NRG-GI002, neither veliparib or pembrolizumab significantly improved short-term outcomes in unselected patients when added to total neoadjuvant therapy (TNT). This trial provides TNT outcome data for benchmarking in future LARC trials
Listen to the podcasts and download the slides on the selected abstracts.
Update from ASCO GI 2023: upper GI cancer highlights
Conference Update |
25 min
|
Jan 2023
I agree that this educational programme:
Update from ASCO GI - Lower GI highlights
Conference Update |
24 min
|
Jan 2023
I agree that this educational programme:
This educational programme is supported by an Independent Medical Education Grant from Bayer
GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.
Other programmes of interest
Other programmes developed by Asst. Prof. Efrat Dotan
Asst. Prof. Efrat Dotan
Medical Oncologist
Fox Chase Cancer Center
United States (US)
Other programmes developed by Prof. Shubham Pant
Prof. Shubham Pant
Medical Oncologist
MD Anderson Cancer Center
United States (US)
Other programmes developed by Prof. Andrea Sartore-Bianchi
Prof. Andrea Sartore-Bianchi
Medical Oncologist
Niguarda Cancer Center
Italy